depression
DEPRESSION

Depression is a mood disorder wherein the patient have a pervasive sad mood or loss of interest in most activities for at least 2 weeks.

It can cause significant distress & impairment. It is also a chronic, episodic and relapsing syndrome.

Treatment can either be by psychotherapy alone or pharmacotherapy alone or psychotherapy combined with pharmacological therapy.

Follow Up

 Follow-up After Acute Phase Treatment

  • Provide frequent follow-up during the 1st 2-4 months of therapy until remission occurs (acute phase)
    • Monitor for adverse drug effects, response to therapy
    • Assess degree of danger to self or others
    • Monitor symptomatic and functional status
    • Follow for switch to mania
  • Re-assess therapy after 4-8 weeks
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 15 hours ago
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.